Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria Fabiane Raquel MotterJanaína Soder FritzenVera Maria Vieira Paniz Review 27 March 2018 Pages: 679 - 700
Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants Charlotte H. MadenDavid FairmanRichard P. Marshall Clinical Trial Open access 12 March 2018 Pages: 701 - 709
Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population Marwa AjmiAsma OmezzineAli Bouslama Pharmacogenetics 26 February 2018 Pages: 711 - 722
CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients Daohua ShiTiancheng XieWeizhen Wu Pharmacogenetics 15 March 2018 Pages: 723 - 729
The steady state pharmacokinetics of trientine in Wilson disease patients Jan PfeiffenbergerCarlot KruseKarl Heinz Weiss Pharmacokinetics and Disposition 07 February 2018 Pages: 731 - 736
The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases Bart A. W. JacobsNikol SnoerenRichard van Hillegersberg Pharmacokinetics and Disposition 11 February 2018 Pages: 737 - 744
Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects Shuaibing LiuLing XueXin Tian Pharmacokinetics and Disposition 13 February 2018 Pages: 745 - 754
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban Ruijuan XuWeihong GeQing Jiang Pharmacokinetics and Disposition 17 February 2018 Pages: 755 - 765
Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals Ferdows AtiqEdon HameliBrenda C. M. de Winter Pharmacokinetics and Disposition Open access 02 March 2018 Pages: 767 - 773
Role of (−)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers Osamu AbeTomoyuki OnoShingen Misaka Pharmacokinetics and Disposition 26 February 2018 Pages: 775 - 783
How do different extracorporeal circulation systems affect metoprolol bioavailability in coronary artery bypass surgery patients Hannu KokkiMartin MaaroosJuha Hartikainen Pharmacokinetics and Disposition 09 March 2018 Pages: 785 - 792
A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy Christelle RodriguesStéphanie ChhunVincent Jullien Pharmacokinetics and Disposition 21 March 2018 Pages: 793 - 803
Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology Domenico MotolaAlberto VaccheriStefano Bianchi Pharmacoepidemiology and Prescription 10 February 2018 Pages: 805 - 810
A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs Minette-Joëlle ZeukengEnrique Seoane-VazquezPascal Bonnabry Pharmacoepidemiology and Prescription 22 February 2018 Pages: 811 - 818
Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis Tejas K. PatelParvati B. Patel Pharmacoepidemiology and Prescription 19 March 2018 Pages: 819 - 832
Conflicting meal recommendations for oral oncology drugs: pose risks to patient care? Guo YuDan-Na WuHong-Hao Zhou Point of View 13 March 2018 Pages: 833 - 842
Clinical pharmacology in Stockholm 50 years—report from the jubilee symposium Michel EichelbaumMarja-Liisa DahlFolke Sjöqvist Conference Report Open access 27 February 2018 Pages: 843 - 851